Pramlintide acetate
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Non-Insulin-Dependent
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Trial Timeline
Aug 1, 2002 → Sep 1, 2002
NCT ID
NCT00044707About Pramlintide acetate
Pramlintide acetate is a phase 2 stage product being developed by AstraZeneca for Diabetes Mellitus, Non-Insulin-Dependent. The current trial status is completed. This product is registered under clinical trial identifier NCT00044707. Target conditions include Diabetes Mellitus, Non-Insulin-Dependent.
What happened to similar drugs?
20 of 20 similar drugs in Diabetes Mellitus, Non-Insulin-Dependent were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01708044 | Phase 1 | Completed |
| NCT00313183 | Phase 2 | Completed |
| NCT00240253 | Approved | Completed |
| NCT00229658 | Pre-clinical | Completed |
| NCT00112021 | Phase 2 | Completed |
| NCT00444561 | Phase 2 | Completed |
| NCT00108004 | Phase 3 | Completed |
| NCT00107107 | Phase 3 | Completed |
| NCT00044707 | Phase 2 | Completed |
| NCT00042471 | Phase 2 | Completed |
Competing Products
20 competing products in Diabetes Mellitus, Non-Insulin-Dependent